Maraviroc Efficacy for Hepatitis C (NCT02881762) | Clinical Trial Compass
CompletedPhase 4
Maraviroc Efficacy for Hepatitis C
United States10 participantsStarted 2017-06-01
Plain-language summary
This is a single-site, longitudinal, open-label, interventional study for evaluating the effect of maraviroc on hepatitis C viral levels in patients infected with both hepatitis C and human immunodeficiency virus (HIV) and taking antiretroviral therapy for HIV.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18 years old
✓. Hepatitis C-infected without plans to undergo hepatitis C treatment for duration of the study
✓. Human immunodeficiency virus (HIV) infected
✓. Currently receiving anti-retroviral therapy with HIV viral load \<50 IU/ml for ≥ 12 months
✓. CD4 T cell counts \> 100 cells/mm3
✓. Non-cirrhotics and cirrhotics can be included
✓. Willing to sign informed consent
Exclusion criteria
✕. Age \< 18
✕. Unable to comply with study visits, research study visits, or is planning to relocate during the study.
✕. Have any condition that the investigator considers a contraindication to study participation
✕. Pregnancy or breast feeding
✕. Decompensated liver disease (Child-Pugh C)
✕. Imminent treatment for hepatitis C infection
✕. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 times the upper limits of normal
What they're measuring
1
The Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc
. Concomitant use of drugs known to impact or be impacted in terms of pharmacokinetics or drug-drug interactions with either raltegravir, dolutegravir, or maraviroc. This includes: